Gallbladder Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, China, India - Size and Forecast 2024-2028
| Published: Dec 2023 | Pages: 166 | SKU: IRTNTR73560 |
Gallbladder Cancer Therapeutics Market 2024-2028
The global gallbladder cancer therapeutics market size is estimated to grow by USD 141.47 million at a CAGR of 6.63% between 2023 and 2028.
The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The market is dominated by using chemotherapy drugs, including gemcitabine, cisplatin, 5-FU, capecitabine, and oxaliplatin. Despite the therapeutic efficacy of these drugs, they are also associated with potential side effects. Moreover, the lack of disease-modifying drugs is another prominent unmet need for the treatment of gallbladder cancer. To overcome this challenge, various market players are conducting heavy research on developing novel therapies such as biologics with mechanisms of action such as PD-1 inhibitors. Thus, such factors are expected to drive the market in focus during the forecast period.
Technavio has segmented the market into Type, Application, and Geography
- The type segment includes combination therapy and monotherapy
- The application segment includes hospitals, academic and medical centers, and others
- The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
What will be the size of the Gallbladder Cancer Therapeutics Market During the Forecast Period?
To learn more about this report, Download Report Sample
Gallbladder Cancer Therapeutics Market Segmentation by Type, Application, and Geography Analysis
Type Analysis
Combination therapy
The market share growth by the combination therapy segment will be significant during the forecast period. Combination therapy involves the use of two or more chemotherapy drugs to achieve a synergistic clinical outcome. This segment offers various combination therapies, among which gemcitabine and cisplatin therapy is the most commonly used treatment regimen. The use of combination therapy depends on the stage of cancer; since most gallbladder cancer cases are diagnosed at an advanced stage, it necessitates the use of combination therapy along with radiation therapy after cholecystectomy.
Get a glance at the market contribution of various segments Download PDF Sample
The combination therapy segment was valued at USD 170.25 million in 2018. The cost of combination therapies is high. However, the treatment using combination therapy requires less frequent dosing and shorter durations when compared with monotherapy. This leads to a decreased financial burden on patients and increases patient adherence to these drugs. However, these drugs are associated with more side effects than monotherapy, which poses a challenge to market growth. The increasing advances in immunotherapy research are expected to help overcome the challenges associated with side effects. Owing to these factors, the combination therapy segment of the market is expected to witness an accelerating growth momentum during the forecast period.
Application Analysis
Hospitals
Hospitals play a vital role in gallbladder cancer therapeutics by providing a range of medical services, including diagnosis, surgery, chemotherapy, and supportive care. Hospitals also contribute to research, clinical trials, and the implementation of innovative therapies, contributing significantly to advancements in gallbladder cancer treatment. The growth of hospitals in the global gallbladder cancer therapeutics market is influenced by factors such as increasing incidence of gallbladder cancer, advancements in medical technologies, and a growing emphasis on early diagnosis and treatment. Additionally, the expansion of specialized oncology departments within hospitals further contributes to the overall growth of gallbladder cancer treatment options, thus propelling the hospitals segment growth in the market during the forecast period.
Academic and medical centers
The growth of academic and medical centers in the global gallbladder cancer therapeutics market involves advancements in research, innovative treatments, and collaborative efforts. These centers play a key role in developing new therapies, conducting clinical trials, and educating professionals to improve patient outcomes. Furthermore, the combined efforts of academic and medical centers contribute significantly to the growth and improvement of the academic and medical centers segment for gallbladder cancer therapeutics, hence contributing to the growth of the market in focus during the forecast period.
Regional Analysis
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2023, North America accounted for the highest share of the global gallbladder cancer therapeutics market, primarily due to the high sales of approved therapeutics and the increased R&D practices undertaken by major players in the market. Moreover, factors such as the increasing awareness about the disease and the growing need for treating it in its early stages are contributing to the market growth. Furthermore, the presence of advanced healthcare infrastructure in the region and the availability of various patient assistance programs are expected to contribute to market growth. Also, the increased focus of key vendors on investing in R&D activities to maintain their market position is anticipated to have a positive impact on the market during the forecast period.
Key Gallbladder Cancer Therapeutics Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 17 market companies, including:
AbbVie Inc.: The company offers gallbladder cancer therapeutics such as ABBV-706 which is an antibody-drug conjugate treatment.
- AstraZeneca Plc
- B.Braun SE
- Boston Scientific Corp.
- Bristol Myers Squibb Co.
- Conmed Corp.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Medtronic Plc
- Merck KGaA
- Novartis AG
- Olympus Corp.
- Pfizer Inc.
- Sanofi SA
- Smith and Nephew plc
- Sun Pharmaceutical Industries Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Gallbladder Cancer Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Key Gallbladder Cancer Therapeutics Market Drivers
The strong incidence of gallbladder cancer in developing countries is the key factor driving market growth. The global gallbladder cancer therapeutics market is currently witnessing a rise in the incidence rate of gallbladder cancer in various developing countries of the world. Furthermore, India, Japan, South Korea, and Central/Eastern Europe, including the Czech Republic, Slovakia, and Slovenia, have also reported a higher incidence rate of the disease when compared with the global incidence rate in the same year.
Moreover, the high incidence of gallbladder cancer in these countries can be attributed to the predisposition to carcinogenesis. The genetic predisposition to carcinogenesis originated from the population migration patterns in the Himalayas and Central Asia through the Bering Strait in the past few decades. The strong incidence of gallbladder cancer in these countries has further led to a rise in the patient population, which, in turn, will induce the demand for gallbladder cancer therapeutics and drive the market growth during the forecast period.
Significant Gallbladder Cancer Therapeutics Market Trends
The rising adoption of immunotherapy is the primary trend shaping market growth. Immunotherapy is a cancer treatment that helps strengthen the immune system's ability to find and attack cancer cells. Immunotherapy is being adopted to treat gallbladder cancers that cannot be removed by surgery. Some gallbladder tumors have specific mutations in their DNA, which are more favorably treated by immunotherapy drugs. Two types of immunotherapy, Keytruda (pembrolizumab), and Opdivo (nivolumab), are approved to treat gallbladder tumors with a certain genetic marker called MSI.
Moreover, another immunotherapy called Durvalumab, a type of PD-L1 inhibitor, is under study, which includes a combination of Durvalumab with chemotherapy in previously untreated patients whose cancer is locally advanced, recurrent, or has spread to other parts of the body. Therefore, the presence of such immunotherapy drugs will increase their adoption, thus stimulating the global gallbladder cancer therapeutics market during the forecast period.
Major Gallbladder Cancer Therapeutics Market Challenges
Lack of adequate healthcare infrastructure in developing nations is a challenge that affects market growth. Radiotherapy and chemotherapy devices require ample installation space due to their large size. In underdeveloped and emerging economies such as India and Argentina and in South American and African countries, there is a lack of adequate healthcare infrastructure due to limited healthcare expenditure. This is one of the major factors restraining the adoption of cancer treatment in countries such as India, Brazil, and South Africa.
In addition, the World Health Organization (WHO) recommends at least one teletherapy unit per million population. As per this recommendation, the minimum required number of teletherapy units in India is around 1,250 units as against the presently available 545 units, marking a considerable shortfall of nearly 700 units. Moreover, the high treatment cost associated with cancer led to low adoption of this treatment in developing countries. Thus, such factors are major challenges to the market and will impede the market growth during the forecast period.
Key Gallbladder Cancer Therapeutics Market Customer Landscape
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Gallbladder Cancer Therapeutics Market Customer Landscape
Segment Overview
The gallbladder cancer therapeutics market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
- Type Outlook
- Combination therapy
- Monotherapy
- Application Outlook
- Hospitals
- Academic and medical centers
- Others
- Region Outlook
- North America
- The U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- APAC
- China
- India
- South America
- Chile
- Brazil
- Argentina
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- North America
|
Gallbladder Cancer Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.63% |
|
Market Growth 2024-2028 |
USD 141.47 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.42 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key countries |
US, Canada, UK, China, and India |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., AstraZeneca Plc, B.Braun SE, Boston Scientific Corp., Bristol Myers Squibb Co., Conmed Corp., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Medtronic Plc, Merck KGaA, Novartis AG, Olympus Corp., Pfizer Inc., Sanofi SA, Smith and Nephew plc, and Sun Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
What are the Key Data Covered in this Gallbladder Cancer Therapeutics Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the gallbladder cancer therapeutics market between 2024 and 2028
- Precise estimation of the gallbladder cancer therapeutics market size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of gallbladder cancer therapeutics market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global gallbladder cancer therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global gallbladder cancer therapeutics market 2018 - 2022 ($ million)
- 4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)
- 4.3 Application Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Application Segment 2018 - 2022 ($ million)
- 4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 Combination therapy - Market size and forecast 2023-2028
- Exhibit 34: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
- 6.4 Monotherapy - Market size and forecast 2023-2028
- Exhibit 38: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
- 6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)
- Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Application
- 7.1 Market segments
- Exhibit 44: Chart on Application - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Application - Market share 2023-2028 (%)
- 7.2 Comparison by Application
- Exhibit 46: Chart on Comparison by Application
- Exhibit 47: Data Table on Comparison by Application
- 7.3 Hospitals - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
- 7.4 Academic and medical centers - Market size and forecast 2023-2028
- Exhibit 52: Chart on Academic and medical centers - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Academic and medical centers - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Academic and medical centers - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Academic and medical centers - Year-over-year growth 2023-2028 (%)
- 7.5 Others - Market size and forecast 2023-2028
- Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
- 7.6 Market opportunity by Application
- Exhibit 60: Market opportunity by Application ($ million)
- Exhibit 61: Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 UK - Market size and forecast 2023-2028
- Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.9 China - Market size and forecast 2023-2028
- Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.10 Canada - Market size and forecast 2023-2028
- Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
- 9.11 India - Market size and forecast 2023-2028
- Exhibit 99: Chart on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on India - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on India - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings
- 12.4 B.Braun SE
- Exhibit 115: B.Braun SE - Overview
- Exhibit 116: B.Braun SE - Business segments
- Exhibit 117: B.Braun SE - Key news
- Exhibit 118: B.Braun SE - Key offerings
- Exhibit 119: B.Braun SE - Segment focus
- 12.5 Boston Scientific Corp.
- Exhibit 120: Boston Scientific Corp. - Overview
- Exhibit 121: Boston Scientific Corp. - Business segments
- Exhibit 122: Boston Scientific Corp. - Key news
- Exhibit 123: Boston Scientific Corp. - Key offerings
- Exhibit 124: Boston Scientific Corp. - Segment focus
- 12.6 Bristol Myers Squibb Co.
- Exhibit 125: Bristol Myers Squibb Co. - Overview
- Exhibit 126: Bristol Myers Squibb Co. - Product / Service
- Exhibit 127: Bristol Myers Squibb Co. - Key news
- Exhibit 128: Bristol Myers Squibb Co. - Key offerings
- 12.7 Conmed Corp.
- Exhibit 129: Conmed Corp. - Overview
- Exhibit 130: Conmed Corp. - Business segments
- Exhibit 131: Conmed Corp. - Key offerings
- Exhibit 132: Conmed Corp. - Segment focus
- 12.8 Eli Lilly and Co.
- Exhibit 133: Eli Lilly and Co. - Overview
- Exhibit 134: Eli Lilly and Co. - Product / Service
- Exhibit 135: Eli Lilly and Co. - Key news
- Exhibit 136: Eli Lilly and Co. - Key offerings
- 12.9 F. Hoffmann La Roche Ltd.
- Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
- 12.10 Gilead Sciences Inc.
- Exhibit 142: Gilead Sciences Inc. - Overview
- Exhibit 143: Gilead Sciences Inc. - Product / Service
- Exhibit 144: Gilead Sciences Inc. - Key news
- Exhibit 145: Gilead Sciences Inc. - Key offerings
- 12.11 Medtronic Plc
- Exhibit 146: Medtronic Plc - Overview
- Exhibit 147: Medtronic Plc - Business segments
- Exhibit 148: Medtronic Plc - Key news
- Exhibit 149: Medtronic Plc - Key offerings
- Exhibit 150: Medtronic Plc - Segment focus
- 12.12 Novartis AG
- Exhibit 151: Novartis AG - Overview
- Exhibit 152: Novartis AG - Business segments
- Exhibit 153: Novartis AG - Key offerings
- Exhibit 154: Novartis AG - Segment focus
- 12.13 Olympus Corp.
- Exhibit 155: Olympus Corp. - Overview
- Exhibit 156: Olympus Corp. - Business segments
- Exhibit 157: Olympus Corp. - Key news
- Exhibit 158: Olympus Corp. - Key offerings
- Exhibit 159: Olympus Corp. - Segment focus
- 12.14 Pfizer Inc.
- Exhibit 160: Pfizer Inc. - Overview
- Exhibit 161: Pfizer Inc. - Product / Service
- Exhibit 162: Pfizer Inc. - Key news
- Exhibit 163: Pfizer Inc. - Key offerings
- 12.15 Sanofi SA
- Exhibit 164: Sanofi SA - Overview
- Exhibit 165: Sanofi SA - Business segments
- Exhibit 166: Sanofi SA - Key news
- Exhibit 167: Sanofi SA - Key offerings
- Exhibit 168: Sanofi SA - Segment focus
- 12.16 Smith and Nephew plc
- Exhibit 169: Smith and Nephew plc - Overview
- Exhibit 170: Smith and Nephew plc - Business segments
- Exhibit 171: Smith and Nephew plc - Key news
- Exhibit 172: Smith and Nephew plc - Key offerings
- Exhibit 173: Smith and Nephew plc - Segment focus
- 12.17 Sun Pharmaceutical Industries Ltd.
- Exhibit 174: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 175: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 176: Sun Pharmaceutical Industries Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources
- 13.5 List of abbreviations
- Exhibit 183: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
gallbladder cancer therapeutics market market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis